Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rebekah Harper

Nurse Practitioner Knoxville, TN Nurse Practitioner

NPI 1811063126 CMS profile 11251554

1450 Dowell Springs Blvd, Suite 300, Knoxville, TN 37909

Open in the dashboard

General payments

$7,657

441 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebekah Harper of Knoxville, TN is reported in the CMS Open Payments database as having received $7,657 across 441 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,401 84
2024 General $1,514 84
2023 General $1,748 102
2022 General $1,819 112
2021 General $1,175 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebekah Harper
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Rebekah Harper were reported at $1,401. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Rebekah Harper Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,175 $135 $40–$426 $132
2022 $1,819 $152 $48–$470 $149
2023 $1,748 $166 $54–$529 $160
2024 $1,514 $173 $55–$556 $164
2025 $1,401 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $842 49 payments
  2. Dexcom, Inc. $799 36 payments
  3. Mannkind Corporation $598 33 payments
  4. Insulet Corporation $555 41 payments
  5. Xeris Pharmaceuticals, Inc. $516 30 payments
  6. Medtronic, Inc. $511 11 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $469 34 payments
  8. Abbott Laboratories $460 30 payments
  9. Novartis Pharmaceuticals Corporation $450 32 payments
  10. Corcept Therapeutics $426 20 payments
  11. Other $2,032 125 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,527 438 payments
  2. Gift $119 2 payments
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Dexcom G6 Transmitter $620 30 payments
  2. AFREZZA $598 33 payments
  3. Omnipod $555 41 payments
  4. Kerendia $469 34 payments
  5. FreeStyle Libre 3 $438 29 payments
  6. Korlym $426 20 payments
  7. JARDIANCE $369 24 payments
  8. MOUNJARO $352 15 payments
  9. LEQVIO $321 24 payments
  10. TRULICITY $233 13 payments
  11. Other $3,655 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

3,613

Median for Nurse Practitioner: 389

Drug cost

$2,654,572

Median for Nurse Practitioner: $21,885

Branded share of claims

68%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 506 $778,893
Ozempic Semaglutide Brand 299 $506,725
Jardiance Empagliflozin Brand 198 $246,233
Tresiba Flextouch U-100 Insulin Degludec Brand 173 $188,871
Tresiba Flextouch U-200 Insulin Degludec Brand 83 $177,108
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 68 $143,792
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 70 $91,820
Novolog Flexpen Insulin Aspart Brand 160 $61,966
Lyumjev Kwikpen U-200 Insulin Lispro-Aabc Brand 11 $56,495
Humalog Kwikpen U-200 Insulin Lispro Brand 19 $43,286

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$72,841

Of which drugs: $5,589

Medicare patients

199

Average age 72

Services billed

3,550

100 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 43%
Chronic kidney disease 39%
Ischemic heart disease 35%
Depression 31%
COPD 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $127
$127 — —
JARDIANCE
  • Lilly USA, LLC $63
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17
$80 198 —
AFREZZA
  • Mannkind Corporation $71
$71 — —
Korlym
  • Corcept Therapeutics $57
$57 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record